Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders.

The Future of Monoclonal Antibodies - WHITEPAPER

ArticleImage

Download the exclusive report

The monoclonal antibodies market continues to grow - according to BIS Research and Research and Markets, monoclonal antibodies (mAbs) are expected to make up just under half of the USD $22.7 billion biologics discovery market in 2025. Engineered or recombinant proteins including next generation antibody therapeutics are expected to contribute $3 billion to the market by 2025. This whitepaper looks at the current state and future of monoclonal antibodies, exploring:

  • FDA approved monoclonal antibodies approved for the first time in 2018

  • Five candidates for FDA approval during Q4 2018, or Q1 2019

  • Monoclonal antibodies in late stage clinical trials

  • Emerging trends in antibody therapeutics

  • The next generation of antibody therapeutics in the next 5-10 years


To download the exclusive report simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.

Have any questions about the report or interested in sponsoring a future report? Email andrew.burrows@informa.com.

Log in or create an Informa Connect account to access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.